Results 41 to 50 of about 7,679 (193)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +1 more source

Mepolizumab effectiveness and identification of super-responders in severe asthma [PDF]

, 2020
Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.The Australian Mepolizumab ...
Reynolds, Paul N., Katsoulotos, Gregory, Hew, Mark, Kritikos, Vicky, Katelaris, Constance, Reddel, Helen, Gillman, Andrew, Grainge, Christopher, Katelaris, Constance H. (R12307), McDonald, Vanessa M., Wark, Peter A B, Wark, Peter A., Katsoulotos, Gregory P., Lee, Joy, Farah, Claude S., Radhakrishna, Naghmeh, Bowden, Jeffrey, Jenkins, Christine, Farah, Claude, Bowler, Simon, Langton, David, Harvey, Erin S., Bowler, Simon D., Chien, Jimmy, Baraket, Melissa, Rimmer, Janet, Upham, John W., Peters, Matthew, Reddel, Helen K., Harrington, John, Stevens, Sean, Chung, Liping, Chung, Li Ping, Bardin, Philip, Gibson, Peter G., Jenkins, Christine R.   +35 more
core   +1 more source

Evaluating treatment response to mepolizumab in patients with severe CRSwNP* [PDF]

, 2023
Background: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP).
Mayer, Bhabita,, Yancey, Steve W., Mayer, Bhabita, Yancey, Steve W.,, Mullol, Joaquim, Lee, Stella E.,, Lund, Valerie J., Lund, Valerie J.,, Smith, Steven G.,, Smith, Steven G., Chan, Robert H.,, Fokkens, Wytske J., Sousa, Ana R., Hopkins, Claire, Lee, Stella E., Hopkins, Claire,, Bachert, Claus, Diamant, Zuzana, Fokkens, Wytske J.,, Han, Joseph K., Mullol, Joaquim,, Yang, Shibing, Han, Joseph K.,, Sousa, Ana R.,, Diamant, Zuzana,, Lund University., Chan, Robert H., Yang, Shibing,   +27 more
core   +1 more source

Mepolizumab

Reactions Weekly
  +14 more sources

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Lynne Bax, Powell, Colin, Bax, Lynne, Nicola Walters, Dwan, Kerry, Walters, Nicola, Milan, Stephen J., Colin Powell, Stephen J Milan, Kerry Dwan   +9 more
core   +1 more source

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Allergy, Asthma & Clinical Immunology, 2019
Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the ...
Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro   +7 more
doaj   +1 more source

Эффективность меполизумаба при длительной терапии тяжелой эозинофильной бронхиальной астмы (клинические наблюдения) [PDF]

, 2019
Two clinical cases of severe eosinophilic asthma taking long-term  therapy with mepolizumab  (38 and 45 months are described in the article. Both the cases demonstrate  the effectiveness of the drug both in allergic and non-allergic  (aspirin-induced ...
А. Ф. Иванов, A. F. Ivanov, И. И. Воржева, I. I. Vorzheva, Б. А. Черняк, B. A. Chernyak   +5 more
core   +2 more sources

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

BMC Pulmonary Medicine, 2019
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance ...
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab

Gastro Hep Advances, 2022
Eosinophilic gastroenteritis is an eosinophilic inflammatory disease that responds well to steroids but often relapses upon their discontinuation, necessitating maintenance treatment.
Yuki Hirata, Takahiko Nakamura, Kazuhide Higuchi   +2 more
doaj   +1 more source

Table1_A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system.DOCX [PDF]

, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Cuilian Guo (17595876), Chongshu Wang (17595873), Aiping Deng (3070284), Huqun Li (3545402)   +3 more
core   +1 more source